SCHEMBL6024063

SCHEMBL6024063

CCS(=O)(=O)c1ccc(C(=C2CCOC2=O)c2cccc(Cl)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
ALOX12 P18054 1/20 0.43
RORC P51449 9/20 0.39
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
BRD4 O60885 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
AKR1C3 P42330 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2126896 0.88 AKR1C3 (0.46) TDP1ALDH1A1MAPTALOX12CA1
SCHEMBL2126893 0.88 AKR1C3 (0.46) TDP1ALDH1A1MAPTALOX12CA1
SCHEMBL2126889 0.88 AKR1C3 (0.46) TDP1ALDH1A1MAPTALOX12CA1
SCHEMBL8663751 0.86 CA1 (0.52) MAPTCA1CA2CA12CA7
SCHEMBL7814069 0.86 CA1 (0.52) MAPTCA1CA2CA12CA7
SCHEMBL7813772 0.79 PTGS2 (0.42) AKR1C3AKR1C2AKR1C1
SCHEMBL7813773 0.79 PTGS2 (0.42) AKR1C3AKR1C2AKR1C1
SCHEMBL7806930 0.77 PTGS2 (0.46) AKR1C3AKR1C2AKR1C1
SCHEMBL1782770 0.77 PTGS2 (0.46) AKR1C3AKR1C2AKR1C1
SCHEMBL1079805 0.77 PTGS2 (0.46) AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670417-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHENIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY Pharmacia Corporation (US) 2006-06-21 EP disclosed
WO-2005037193-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY PHARMACIA CORPORATION (US) 2005-04-28 WO disclosed